Creatine Monohydrate Effects on Retinal Angiogenesis
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Boston Children's Hospital, Harvard University, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Tokyo Medical University Hospital, University of Gothenburg, Merck & Co., Inc., Rahway, NJ, USA (United States)
Variable analysis
- Creatine monohydrate (500 mg/kg)
- PBS (control)
- Areas of retinal neovascularization (NV)
- Areas of vaso-obliteration (VO)
- Mouse strain (C57BL/6J)
- Mouse sex (male and female)
- Oral gavage administration
- Daily treatment from P12 to P16
- Retinal staining with Alexa Fluor 594-conjugated isolectin GS-IB4
- Visualization using epifluorescence microscope
- Exclusion of mice weighing less than 5.0 g
- Positive control: Creatine monohydrate treatment group
- Negative control: PBS (vehicle) group
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!